Theriva Biologics
Yahoo Finance • last year
Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer
- Theriva signs exclusive option to license intellectual property from Sant Joan de Déu-BarcelonaChildren’s Hospital (SJD) to explore the therapeutic potential of VCN-01 in combination with topoisomerase I inhibitors - - Strengthens long-... Full story
Yahoo Finance • last year
Theriva™ Biologics y el Hospital Infantil Sant Joan de Déu Barcelona avanzan en su colaboración estratégica para estudiar la combinación del VCN-01 con inhibidores de la topoisomerasa para tratar el cáncer
- Theriva firma la opción de licencia exclusiva de propiedad intelectual del Hospital Infantil Sant Joan de Déu Barcelona (SJD) para explorar el potencial terapéutico del VCN-01 en combinación con inhibidores de la topoisomerasa I - - Ref... Full story
Yahoo Finance • 2 years ago
Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results
– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Presented data from the ongoing Phase 1b/2a clinical trial... Full story
Yahoo Finance • 2 years ago
Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results
ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today annou... Full story
Yahoo Finance • 2 years ago
Theriva Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2023
ROCKVILLE, Maryland, May 04, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran... Full story
Yahoo Finance • 2 years ago
Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in the investigator sponsored Phase 1 cli... Full story
Yahoo Finance • 2 years ago
Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today ann... Full story
Yahoo Finance • 2 years ago
Theriva Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del cuarto trimestre y del ejercicio 2022
ROCKVILLE, Maryland, March 20, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gr... Full story
